Cargando…

Cho B-S, Zeng Z, Mu H, et al. Antileukemia activity of the novel peptidic CXCR4 antagonist LY2510924 as monotherapy and in combination with chemotherapy. Blood. 2015;126(2):222-232.

Detalles Bibliográficos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society of Hematology 2015
Materias:	Errata
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4543225/ http://dx.doi.org/10.1182/blood-2015-07-657387

Ejemplares similares

Schleicher RI, Reichenbach F, Kraft P, et al. Platelets induce apoptosis via membrane-bound FasL. Blood. 2015;126(12):1483-1493.
Publicado: (2016)

Gill JC, Castaman G, Windyga J, et al. Hemostatic efficacy, safety, and pharmacokinetics of a recombinant von Willebrand factor in severe von Willebrand disease. Blood. 2015;126(17):2038-2046.
Publicado: (2016)

Distinct mobilization of leukocytes and hematopoietic stem cells by CXCR4 peptide antagonist LY2510924 and monoclonal antibody LY2624587
por: Peng, Sheng-Bin, et al.
Publicado: (2017)

Safety and Pharmacokinetics of CXCR4 Peptide Antagonist, LY2510924, in Combination with Durvalumab in Advanced Refractory Solid Tumors
por: O'Hara, Mark H., et al.
Publicado: (2020)

Population Pharmacokinetic and Pharmacodynamic Modeling of LY2510924 in Patients With Advanced Cancer
por: Bihorel, S, et al.
Publicado: (2017)

Initial Report of a Phase I Study of LY2510924, Idarubicin, and Cytarabine in Relapsed/Refractory Acute Myeloid Leukemia
por: Boddu, Prajwal, et al.
Publicado: (2018)

Combining incretin-based therapies with insulin: realizing the potential in type 2 diabetes. Diabetes Care 2013;36(Suppl. 2):S226–S232
por: Vora, J
Publicado: (2013)

C-terminal–modified LY2510924: a versatile scaffold for targeting C-X-C chemokine receptor type 4
por: Suzuki, Kentaro, et al.
Publicado: (2019)

First person – Jianhao Zeng
Publicado: (2023)

Erratum to “Automatic assessment of dairy cows' rumen function over time and links to feed changes and milk production” (JDS Commun. 3:126–131)
por: Song, X., et al.
Publicado: (2022)

Erratum to “Use of a real-time location system to detect cows in distinct functional areas within a barn” (JDS Commun. 2:217–222)
por: Chapa, J.M., et al.
Publicado: (2022)

Erratum. Evaluation of Efficacy and Safety of the Glucagon Receptor Antagonist LY2409021 in Patients With Type 2 Diabetes: 12- and 24-Week Phase 2 Studies. Diabetes Care 2016;39:1241–1249
por: Kazda, Christof M., et al.
Publicado: (2017)

Shouval R, Fein JA, Cho C, et al. The Simplified Comorbidity Index: a new tool for prediction of nonrelapse mortality in allo-HCT. Blood Adv. 2022;6(5):1525-1535.
Publicado: (2022)

Bélanger S, Tu MM, Rahim MM, et al. Impaired natural killer cell self-education and “missing-self” responses in Ly49-deficient mice. Blood. 2012;120(3):592-602.
Publicado: (2013)

Repurposing immunosuppressants for antileukemia therapy
por: Sezaki, Maiko, et al.
Publicado: (2022)

Yi Zeng: promoting good governance of artificial intelligence
por: Jia, Hepeng
Publicado: (2020)

Schinke C, Giricz O, Li W, et al. IL8-CXCR2 pathway inhibition as a therapeutic strategy against MDS and AML stem cells. Blood. 2015;125(20):3144-3152.
Publicado: (2015)

Guang Zeng, China CDC’s Former Chief Expert of Epidemiology
por: Hao, Peter, et al.
Publicado: (2020)

Synthesis and Antileukemia Activity Evaluation of Benzophenanthridine Alkaloid Derivatives
por: Tang, Yaling, et al.
Publicado: (2022)

Dr. Yi Zeng (1929−2020) A Pioneer on HIV and Tumor Virology in China
por: Zhang, Xiaoguang, et al.
Publicado: (2020)

Antileukemia Activity and Mechanism of Platinum(II)-Based Metal Complexes
por: Di Pietro, Maria Letizia, et al.
Publicado: (2022)

Stem cells and art: an interview with Yi Arial Zeng on the promising future of the stem cell field
Publicado: (2021)

AP2α controls the dynamic balance between miR-126&126* and miR-221&222 during melanoma progression
por: Felli, N, et al.
Publicado: (2016)

Formulation, antileukemia mechanism, pharmacokinetics, and biodistribution of a novel liposomal emodin
por: Wang, Tiechuang, et al.
Publicado: (2012)

Silylation of Deoxynucleotide Analog Yields an Orally Available Drug with Antileukemia Effects
por: Ureshino, Hiroshi, et al.
Publicado: (2021)

Network Pharmacological Analysis and Animal Experimental Study on Osteoporosis Treatment with GuBen-ZengGu Granules
por: Wang, Kai, et al.
Publicado: (2023)

Preclinical Antileukemia Activity of Tramesan: A Newly Identified Bioactive Fungal Metabolite
por: Ricciardi, M. R., et al.
Publicado: (2017)

Modeling the Antileukemia Activity of Ellipticine-Related Compounds: QSAR and Molecular Docking Study
por: Márquez, Edgar, et al.
Publicado: (2019)

Synthesis, Antiplasmodial, and Antileukemia Activity of Dihydroartemisinin–HDAC Inhibitor Hybrids as Multitarget Drugs
por: von Bredow, Lukas, et al.
Publicado: (2022)

Inhibition of CXCR4 by LY2624587, a Fully Humanized Anti-CXCR4 Antibody Induces Apoptosis of Hematologic Malignancies
por: Peng, Sheng-Bin, et al.
Publicado: (2016)

Reply to Kesici et al. and Zeng et al.: Blocking the virus and reducing the inflammatory damage in COVID-19
por: Duan, Kai, et al.
Publicado: (2020)

Erratum
Publicado: (1989)

Erratum
Publicado: (1988)

Erratum
Publicado: (1988)

Erratum
Publicado: (1988)

Erratum
Publicado: (1989)

Erratum
Publicado: (2006)

Changes in the geographical and temporal patterns of cancer incidence among black gold miners working in South Africa, 1964–1996
por: McGlashan, N D, et al.
Publicado: (2003)

ERRATUM
Publicado: (1994)

Erratum
Publicado: (1999)

Cannot write session to /tmp/vufind_sessions/sess_mos1qtobtaqndjp6sml86l4bok